Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of “Hold” from Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned an average recommendation of “Hold” from the twenty-three ratings firms that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $60.63.

A number of research firms have recently commented on MRNA. Bank of America dropped their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Wolfe Research began coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. set a $45.00 price objective on Moderna in a research note on Friday, February 14th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Leerink Partners dropped their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th.

Moderna Stock Performance

Moderna stock opened at $30.96 on Wednesday. The business’s 50-day simple moving average is $37.30 and its 200-day simple moving average is $50.90. The firm has a market capitalization of $11.94 billion, a PE ratio of -3.34 and a beta of 1.59. Moderna has a 52 week low of $29.25 and a 52 week high of $170.47.

Institutional Investors Weigh In On Moderna

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB boosted its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC boosted its holdings in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Moderna in the 4th quarter worth approximately $41,000. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after acquiring an additional 343 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.